Novel CD20/CD3 bispecific antibodies in NHL
VJHemOnc Podcast
00:00
Effectiveness and Durability of Novel CD20/CD3 Bispecific Antibodies in NHL
This chapter discusses the effectiveness and durability of novel CD20/CD3 bispecific antibodies in aggressive lymphomas and follicular lymphomas, presenting data on complete response rates and remission off therapy for different patient groups. It highlights the flexibility of bi-specific antibodies by presenting case studies of patients who achieved complete remission after treatment, and mentions their use as a bridge to CAR T-cell therapy and as a retreatment option.
Transcript
Play full episode
